Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie Inc    ABBV

ABBVIE INC (ABBV)

Delayed Quote. Delayed  - 05/25 10:00:51 pm
61.22 USD   +0.86%
06:15pDJFlorida Judge Denies Gawker Motion for New Trial in Hulk Hogan Ca..
05/24 ABBVIE : IL-23 Inhibitor Risankizumab Induces Remission in Phase II ..
05/22 ABBVIE : Personalized cancer drug co in AbbVie collaboration
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
05/19/2016 05/20/2016 05/23/2016 05/24/2016 05/25/2016 Date
59.28(c) 59.69(c) 59.3(c) 60.7(c) 61.22 Last
9 917 904 11 259 353 6 468 921 8 888 080 5 857 029 Volume
-1.95% +0.69% -0.65% +2.36% +0.86% Change
More quotes
Financials ($)
Sales 2016 25 568 M
EBIT 2016 10 729 M
Net income 2016 6 670 M
Debt 2016 27 154 M
Yield 2016 3,70%
Sales 2017 28 156 M
EBIT 2017 12 371 M
Net income 2017 8 226 M
Debt 2017 24 447 M
Yield 2017 4,04%
P/E ratio 2016 14,69
P/E ratio 2017 11,65
EV / Sales 2016 4,90x
EV / Sales 2017 4,36x
Capitalization 98 174 M
More Financials
Company
AbbVie, Inc. is a research-based biopharmaceutical company.It engages in the discovery, development, manufacture and sale of a broad line of proprietary pharmaceutical products.The company's focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and... 
Sector
Pharmaceuticals
Calendar
06/03 | 04:00pmShareholder meeting
More about the company
Surperformance© ratings of AbbVie Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ABBVIE INC
06:15pDJFlorida Judge Denies Gawker Motion for New Trial in Hulk Hogan Case
05/24 ABBVIE : IL-23 Inhibitor Risankizumab Induces Remission in Phase II Study in Pat..
05/22 ABBVIE : Personalized cancer drug co in AbbVie collaboration
05/19 ENANTA PHARMACEUTICALS : Reports Financial Results for its Fiscal Second Quarter..
05/19 BRISTOL MYERS SQUIBB : and AbbVie Announce European Commission Approval of Empli..
05/19 ABBVIE : 's Leadership in Gastroenterology Showcased at Digestive Disease Week® ..
05/17DJPatent Office to Review a Regimen of AbbVie's Humira -- Update
05/17DJPatent Office to Review a Regimen of AbbVie's Humira
More news
Sector news : Specialty & Advanced Pharmaceuticals
10:41p Sanofi moves to oust Medivation board in $9.3 billion takeover fight
10:35p Sanofi moves to oust Medivation board in $9.3 billion takeover fight
10:02p POSSIBLE TAKEOVER OF MONSANTO COMPAN : MON) Faces Investigation for Investors
More sector news : Specialty & Advanced Pharmaceuticals
4-Traders Strategies on ABBVIE INC 
2015A likely recovery
More Strategies
News from SeekingAlpha
11:51a ABBOTT LABS : Forget Politics, I Am Pounding The Table
09:30a Achillion's Pipeline Strengthens, With Near-Term Potential Catalysts
09:02a BIOTECH FORUM DAILY DIGEST : The Biotech Rally Continues, Relypsa Gets Some Trac..
06:59a Galapagos and Gilead on go to start late-stage filgotinib development in RA
05/24 In-House Projects An Ever-Thinner Slice Of Sales For Big Pharma


Comments 
Advertisement
Chart ABBVIE INC
Duration : Period :
AbbVie Inc Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Full-screen chart
Technical analysis trends ABBVIE INC
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions